Ascendia

  MARKET NEWS

Atavistik Bio Announces Publication Describing Foundational Technology for its AMPS Platform
Nemera Reinforces Commitment to Sustainability With First Integrated ESG Report
Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time & Accelerate Path to Clinic
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib 
Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study for Patients With Moderate-to-Severe Atopic Dermatitis
QSAM Biosciences Receives FDA Clearance to Expand Enrollment Criteria in its Phase 1 Study Targeting Metastatic Bone Cancer

  FEATURED EDITORIAL

  COMPANY PROFILE

Actylis is a leading manufacturer of critical raw materials and performance ingredients serving the Life Sciences industry. Through our hybrid approach we provide combined capabilities in GMP manufacturing and global sourcing of critical raw materials and ingredients, offering unrivaled choice to pharmaceutical & biopharmaceutical companies. The inherent flexibility in our hybrid approach alleviates common internal customer concerns over time constraints in delivery to market and capacity pressures. We enable customers to consolidate their supply chain with one reliable partner, backed by best-in-class quality and regulatory accreditation, while retaining valuable flexibility. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cingulate & Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate

Cingulate & Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate

Cingulate Inc. and Indegene recently announced a joint commercialization agreement to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment….

Aenova Introduces New Sterile Strategy

Aenova Introduces New Sterile Strategy

Aenova Group, a leading international contract developer and manufacturer for the pharmaceutical and healthcare industries, presents its new sterile strategy…..

First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

First Wave BioPharma, Inc. recently announced that the first patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of….

Evonik Opens New Facility for Pharmaceutical Lipids at Site in Germany

Evonik Opens New Facility for Pharmaceutical Lipids at Site in Germany

Evonik is opening a new GMP facility to manufacture lipids for advanced, pharmaceutical drug delivery applications. The lipid launch facility is located at the company’s site in Hanau, Germany and….

BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.

BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.

BioStem Technologies Inc. recently announced it has entered into an agreement to acquire the majority of the assets of Auxocell Laboratories, Inc., a leading solid tissue processing equipment manufacturer…..

  WHITEPAPERS & WEBINARS

 

WEBINAR - Step Into the Future of Therapeutic Antibody Discovery

WEBINAR - Step Into the Future of Therapeutic Antibody Discovery

Join us to hear about our new biotherapeutic antibody discovery service — the Pioneer Platform, and how it can help you find your next lead candidate.

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*

Summary

The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …

WHITEPAPER WORKSHOP - Soft Mist Inhalers

WHITEPAPER WORKSHOP - Soft Mist Inhalers

Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.

The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 22 – Excipients
March 29 – Prefilled Syringes